Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients

- **Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe**
- **The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies**

Paris, France – 24 February, 2023 – Servier, a global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Tibsovo® (ivosidenib tablets) - an inhibitor of the mutated isocitrate dehydrogenase-1 (IDH1) enzyme - for two indications:

- in combination with azacitidine, for the treatment of adult patients with newly diagnosed IDH1-mutated Acute Myeloid Leukemia and not eligible for standard induction chemotherapy,
- in monotherapy, for the treatment of adult patients with locally advanced or metastatic IDH1-mutated Cholangiocarcinoma, previously treated by at least one prior line of systemic therapy.

Claude Bertrand, Executive Vice President R&D of Servier, said: *"The positive CHMP opinion is a further step towards the availability, in the European Union, of Tibsovo® which is the first IDH1 inhibitor to be recommended for approval in Europe for patients with Acute Myeloid Leukemia and Cholangiocarcinoma for whom therapeutic options are very limited. Tibsovo® is an illustration of the Group's transformation and commitment in oncology which focuses its research on hard-to-treat cancers with the development of targeted therapies being a promising path for patients."*

The positive CHMP opinion is based on clinical data from the AGILE (AML) and ClarIDHy (CCA) studies.

Prof Hartmut Döhner, Medical Director of the Department of Internal Medicine at the University Hospital in Ulm, Germany, stated: *"This is an important milestone in improving treatments for patients with Acute Myeloid Leukemia. Approximately 8% of patients with this type of blood cancer has an IDH1 mutation, and for those patients this effective precision medicine is an important treatment option that has robust evidence for improving overall survival and, importantly, also quality of life."*

John Bridgewater, MD, Ph.D., Professor and consultant in Medical Oncology, UCL Cancer Institute, and University College London Hospital in London UK, declared*: "This is great news for patients with advanced Cholangiocarcinoma, a cancer with a very poor outlook and limited treatment options. For approximately 15% who have an IDH1 mutation, this will now offer a valuable treatment option. Now we have to encourage the oncology community to embrace the principle of personalized oncology to improve the outlook on well-being of our very needy patients."*

AML is a cancer of the blood and bone marrow marked by rapid disease progression. It is the most common acute leukemia in adults and affects 5/100,000 inhabitants in Europe, i.e., more than 20,000 new cases each year.[1] The two-year survival rate of 75 years-old patients with AML is below 10%.[2]

Cholangiocarcinoma, a cancer of the bile ducts, is a rare and aggressive tumor often linked to medical history such as cirrhosis or liver infection. Cholangiocarcinoma affects 1–3/100,000 inhabitants in Europe, i.e., approximately 10,000 new cases each year in Europe.[3] The five-year survival rate is 9%, but 0% if metastasized.[4] Only surgery can cure patients, but the treatment is only possible for a limited number of patients and the risk of relapse remains high. Chemotherapy and immunotherapy are the standard therapies for patients with cholangiocarcinoma who are not eligible for surgery or whose disease has progressed after surgery.

Tibsovo® is approved by the US FDA in combination with azacitidine or as monotherapy for the treatment of IDH1-mutant newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy and as monotherapy for the treatment of adults with IDH1-mutant relapsed or refractory AML. Tibsovo® is also approved in the US for patients with previously treated, locally advanced or metastatic IDH1-mutated Cholangiocarcinoma. Tibsovo® is approved by the NMPA of China for the treatment of adult patients with relapsed or refractory AML who have a susceptible IDH1 mutation.[5]

The CHMP's positive opinion on Tibsovo® in IDH1 mutated AML and CCA patients will be referred to the European Commission (EC) which will deliver a final decision in the coming months. The decision will be applicable to all 27 EU member states plus Iceland, Norway, Northern Ireland and Liechtenstein.

Find out more about cholangiocarcinoma and acute myeloid leukemia on servier.com.

Press contact
Sonia Marques: presse@servier.com I Tel. +33 (0)1 55 72 40 21

About Servier

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,400 employees of the Group are committed to this shared vocation, source of inspiration every day.

As a world leader in cardiology, Servier's ambition is to become a renowned, focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 50% of its R&D budget to developing targeted and innovative therapies in oncology.

[1] ESMO Guidelines 2020 - Acute myeloid leukemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
[2] Shallis R. - Blood reviews 36 (2019) 70-87.
[3] Valle JW, et al. *Ann Oncol.* 2016;27(Suppl. 5):v28–v37
[4] Oliveira IS, et al. *Abdom Radiol (NY).* 2017;42(6):1637–1649
[5] Servier has granted to CStone a co-exclusive license for the development and an exclusive license agreement for commercialization of Tibsovo (ivosidenib tablets) in Mainland China, Taiwan, Hong Kong, Macau and Singapore.

Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.

In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €4.9 billion in 2022. More information on the new Group website: servier.com

Follow us on social media: LinkedIn, Facebook, Twitter, Instagram